> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Agrees to Abridged Trial for Wockhardt’s ‘Super’ Antibiotic
- URL: https://www.fdaweb.com/fda-agrees-to-abridged-trial-for-wockhardts-super-antibiotic/
- Published: 2017-04-03T12:00:00.000Z
- Updated: 2026-09-14T22:15:37.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138355

FDA has agreed to an abridged Phase 3 clinical trial for Wockhardt’s WCK 5222, a “superdrug” antibiotic, according to the company. The agency’s decision was based on preclinical and Phase 1 clinical data establishing safety and the clinical scope of efficacy for the drug, it says. WCK 5222 is a combination of zidebactam and cefepime, Wockhardt says, adding that it is expected to be a life saving therapy for serious hospital acquired infections such as pneumonia, ventilator associated pneumonia and blood stream infections.